Drug Profile
JTT 251
Alternative Names: JTT-251Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Akros Pharma
- Class Antihyperglycaemics; Heart failure therapies
- Mechanism of Action Pyruvate dehydrogenase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Heart failure
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO, Tablet)
- 31 Oct 2019 Phase I development in Type 2 diabetes mellitus is ongoing in USA
- 01 May 2019 Akros Pharma withdraws the phase II RELIEF-PAH trial for Pulmonary arterial hypertension as per corporate decision and priority change (PO, Tablet) (NCT03789643)